GlycoMimetics' GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML
Data presented via poster at
The results, presented at the
"The data from the Phase 1 portion of this Phase 1/2 trial are very
encouraging, demonstrating a high remission rate; and the combination of
GMI-1271 and chemotherapy seems to be extremely well tolerated," said
The poster (P191), entitled "Results of a Phase 1 study of GMI-1271, a potent E-selectin antagonist in combination with induction chemotherapy in relapsed/refractory AML: a novel, well-tolerated regimen with a high remission rate," is available here and will be displayed as part of a poster session scheduled for 5:15 p.m. CET today.
AML is a cancer of immature white blood cells that starts in the bone
marrow but can quickly spread into the blood, lymph nodes, liver,
spleen, central nervous system and soft tissues. Each year in
GMI-1271 is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with AML cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. Preclinical research points to the drug's potential role in moving cancerous cells out of the protective environment of the bone marrow where they hide and escape the effects of chemotherapy. In preclinical studies using animal models of AML, the results of which were presented at meetings of the American Society of Hematology (ASH), GMI-1271 was also associated with a reduction of chemotherapy-induced neutropenia and chemotherapy-induced mucositis.
News Provided by Acquire Media